Brand LaunchThe upcoming launch of a third brand in medical-grade skincare is anticipated to be a positive catalyst for the stock.
Growth And Margin OutlookThe company's robust growth and margin outlooks, along with strategic plans to develop new products, support the goal of maintaining a 20% EBITDA growth trajectory.
Valuation And Financial PerformanceThe company's valuation is considered compelling given its 20% growth outlook, and there is room for financial outperformance and multiple expansion.